News

Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin Regimen With or Without Blinatumomab Demonstrates Efficacy, Safety for R/R Pre-B ALL

07/06/2023

Jordan Kadish

Mini-hyper-CVD plus inotuzumab with or without blinatumomab showed efficacy in patients with relapsed/refractory pre-B ALL, with improved survival after the addition of blinatumomab, according to an updated analysis of a phase 2 trial.

Mini-hyper-CVD plus inotuzumab...

07/06/2023

Oncology

News

Donor-Derived CD7 CAR T-Cell Therapy Demonstrated Durable Efficacy Among Subset of Patients With R/R T-Cell ALL

06/22/2023

Jordan Kadish

2-year follow-up results from a phase 1 study indicated that donor-derived CD7 CAR T-cell therapy demonstrated durable efficacy among a subset of patients with R/R T-cell acute lymphoblastic leukemia.

2-year follow-up results from a...

06/22/2023

Oncology

News

Dose-Adjusted EPOCH Regimen Yielded Deep and Durable Remissions Among Patients With ALL

05/18/2023

Jordan Kadish

According to findings from a phase 2 trial, a dose-adjusted EPOCH regimen yielded deep and durable remissions among patients with ALL and was comparable to some resource-intensive strategies of treatment.

According to findings from a...

05/18/2023

Oncology

News

Intramuscular JZP458 for Patients With AML With Hypersensitivity to E. Coli-Derived Asparaginases

04/14/2023

Jordan Kadish

According to findings of a phase 2/3 trial, intramuscular JZP458 yielded safe and effective results among patients with ALL or lymphoblastic leukemia with hypersensitivity/silent inactivation to asparaginases.

According to findings of a phase...

04/14/2023

Oncology

News

Inotuzumab Ozogamicin Induction Yielded High Remission Rates in Older Adults With De Novo Acute B-Lymphoblastic Leukemia

02/08/2023

Jordan Kadish

Inotuzumab ozogamicin induction therapy for adults with de novo acute B-lymphoblastic leukemia resulted in high remission rates, according to a phase 2 study.

Inotuzumab ozogamicin induction...

02/08/2023

Oncology

News

Blinatumomab During Consolidation May Benefit Patients With High-Risk Ph-Negative BCP Acute Lymphoblastic Leukemia

02/08/2023

Jordan Kadish

Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...

Results from the GRAALL-2014/B...

02/08/2023

Oncology

News

Chemotherapy Plus Ponatinib Followed by Transplant Well-Tolerated in Adults With Philadelphia–Positive ALL

10/18/2022

Gina Tomaine

The combination of chemotherapy with ponatinib followed by alloHSCT is well-tolerated in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia, according to a phase 2 trial.

The combination of chemotherapy...

10/18/2022

Oncology

News

Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide for ALL

09/20/2022

Gina Tomaine

Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.

Busulfan plus cyclophosphamide...

09/20/2022

Oncology

News

Long-Term Results of ASCT in Adult High-Risk Acute Lymphoblastic Leukemia

09/13/2022

Gina Tomaine

Matched sibling and unrelated donor-based allogeneic hematopoietic stem cell transplantations in patients with BCR-ABL-negative acute lymphoblastic leukemia yielded similar long-term outcomes.

Matched sibling and unrelated...

09/13/2022

Oncology

News

Entinostat Plus Clofarabine Demonstrates Promising Safety, Efficacy for Philadelphia Chromosome-Negative ALL

06/18/2022

John Otrompke

The histone deacetylase inhibitor entinostat plus clofarabine is active and tolerable in older, newly-diagnosed patients with Philadelphia chromosome-negative ALL and ABL.

The histone deacetylase...

06/18/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology